目的 觀察百癬夏塔熱膠囊聯(lián)合枸地氯雷他定治療慢性蕁麻疹的臨床療效。方法 選取2015年10月—2017年5月東莞市茶山醫(yī)院收治的慢性蕁麻疹患者84例，隨機(jī)分為對(duì)照組和治療組，每組各42例。對(duì)照組口服枸地氯雷他定片，1片/次，1次/d。治療組在對(duì)照組治療基礎(chǔ)上口服百癬夏塔熱膠囊，35~45 kg者，2粒/次，2次/d；45 kg及以上者，2粒/次，3次/d。兩組患者均連續(xù)治療4周。觀察兩組的臨床療效，比較兩組治療前后癥狀積分、血清學(xué)指標(biāo)和免疫功能的變化情況。對(duì)兩組進(jìn)行3個(gè)月的隨訪，觀察復(fù)發(fā)情況。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為71.43%、90.48%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，兩組皮膚瘙癢積分、風(fēng)團(tuán)直徑積分、風(fēng)團(tuán)數(shù)目積分、免疫球蛋白E（IgE）、白細(xì)胞介素-4（IL-4）、IL-18、IL-33、CD⁸⁺均顯著降低，干擾素-γ（IFN-γ）、CD⁴⁺、CD⁴⁺/CD⁸⁺明顯上升，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）；治療后，治療組皮膚瘙癢積分、風(fēng)團(tuán)直徑積分、風(fēng)團(tuán)數(shù)目積分、IgE、IL-4、IL-18、IL-33、CD⁸⁺均低于對(duì)照組，IFN-γ、CD⁴⁺、CD⁴⁺/CD⁸⁺高于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。隨訪期間，對(duì)照組和治療組的復(fù)發(fā)率分別為19.05%、2.38%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）。結(jié)論 百癬夏塔熱膠囊聯(lián)合枸地氯雷他定治療慢性蕁麻疹具有較好的臨床療效，可改善患者癥狀和免疫狀態(tài)，同時(shí)可有效降低復(fù)發(fā)率，具有一定的推廣應(yīng)用價(jià)值。

Objective To observe the clinical efficacy of Baixuan Xiatare Capsules combined with desloratadine citrate disodium in treating of chronic urticarial. Methods Patients (84 cases) with chronic urticaria in Chashan Hospital of Dongguan from October 2015 to May 2017were randomly divided into control (42 cases) and treatment (42 cases) groups. Patients in the control group were po administered with Desloratadine Citrate Disodium Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Baixuan Xiatare Capsules on the basis of the control group, weight from 35 kg to 45 kg, 2 grains/time, twice daily; weight above 45 kg, 2 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the changes of symptom scores, serological indexes and immune function in two groups before and after treatment were compared. The two groups were followed up for 3 months, and the recurrence was observed. Results After treatment, the clinical efficacy in the control and treatment groups were 71.43% and 90.48%, respectively, and there was difference between two groups (P < 0.05). After treatment, skin itch score, wind group diameter score, wind group number score, IgE, IL-4, IL-18, IL-33, and CD⁸⁺ were decreased, but IFN-γ, CD⁴⁺, CD⁴⁺/CD⁸⁺ increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, skin itch score, wind group diameter score, wind group number score, IgE, IL-4, IL-18, IL-33, and CD⁸⁺ in the treatment group were lower than those in the control group, but IFN-γ, CD⁴⁺, CD⁴⁺/CD⁸⁺ were higher than those in the control group, and there was difference between two groups (P < 0.05). During the follow-up period, the recurrence rates of the control group and the treatment group were 19.05% and 2.38% respectively, and there was difference between two groups (P < 0.05). Conclusion Baixuan Xiatare Capsules combined with desloratadine citrate disodium has clinical curative effect in treating of chronic urticarial, and can improve the symptoms and immune status, and can effectively reduce the recurrence rate, which has a certain clinical application value.